Ranbaxy's second quarter sales up by 11%
This article was originally published in Scrip
Executive Summary
Ranbaxy Laboratorieshas reported an 11% increase in consolidated sales to $440 million for the second quarter ended June 30th, backed by 12% growth in sales in developed markets. Profit after tax (excluding the foreign exchange gains/losses on translation) was flat at $39 million.